Tivdak gets primary endpoint in PhIII confirmatory study

Gen­mab and Seagen’s cer­vi­cal can­cer drug Tiv­dak has reached its pri­ma­ry end­point in a con­fir­ma­to­ry Phase III tri­al, and the re­sults are ex­pect­ed to sup­port their bid to pur­sue full ap­proval of the an­ti­body-drug con­ju­gate in cer­vi­cal can­cer.

The FDA in 2021 grant­ed Tiv­dak, al­so known as ti­so­tum­ab ve­dotin-tftv, an ac­cel­er­at­ed ap­proval as a sec­ond-line treat­ment for pa­tients with re­cur­rent or metasta­t­ic cer­vi­cal can­cer af­ter chemother­a­py or dis­ease pro­gres­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.